Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
about
Trabectedin for Soft Tissue Sarcoma: Current Status and Future PerspectivesTrabectedin in soft tissue sarcomasTrabectedin for the management of soft-tissue sarcoma.New developments in treatment of ovarian carcinoma: focus on trabectedinCombination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma.Trabectedin: safety and efficacy in the treatment of advanced sarcomaA comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cellsPhase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignanciesTrabectedin: an anticancer drug from the sea.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Trabectedin: novel insights in the treatment of advanced sarcoma.Trabectedin for the treatment of breast cancer.Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options.The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.Efficacy of trabectedin for the treatment of liposarcoma.Current questions in soft tissue sarcoma: further steps with Yondelis®.Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.
P2860
Q26745502-C7F26306-7D76-44D8-870B-1B994C802D38Q28085505-8A4919A5-0D3C-4F83-814A-178A8B936101Q33384836-A859310B-896A-41AC-A15F-6D7BB86FB926Q33393429-FA435D40-783F-47B0-BBAD-2C1DE0CC9419Q33419792-30E54EEA-68C9-4ACC-8B9C-5BCA8EE24D6BQ33921802-895506FC-E3EC-458C-B336-DA428F223571Q34622323-C07A4702-299F-4830-90CE-893EFC212C04Q34628607-93C6FC97-288C-4769-9AFF-4AAA7F0558A0Q35246995-9FF0E4B7-F200-47C0-B283-00EEF1787317Q36447737-10DA647A-0177-42D7-BBBA-CC5C926C10E3Q37163139-60AF48AB-4CE2-4AAB-91B0-3059B185EC7DQ37594790-76A0BFC2-6399-407E-ABE5-1BD2DCA7BF52Q37760957-F820430A-1997-42A8-A96A-333659A76FE4Q38206396-EDB03DE3-0027-46DE-962F-55BB23AEDAE5Q38642314-FC121386-BAA1-4427-8636-A23BDE92168DQ38731757-660DF9F4-BF24-43BC-B79F-892015AA13B1Q38797843-56A8821A-4B7C-47B7-BED6-734955068DC0Q38951318-AA3308EB-518A-451D-93DD-B786B1E5DF58Q39422853-FF326135-8138-4ED8-AA5A-6052A2AABAECQ52812855-9DAC6F91-232B-4D7D-960A-8D9CAA39EB95Q55365628-C9ECFBAA-2191-4C68-8CAA-2BC1239AC317
P2860
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Phase I trial of weekly trabec ...... ts with advanced solid tumors.
@ast
Phase I trial of weekly trabec ...... ts with advanced solid tumors.
@en
type
label
Phase I trial of weekly trabec ...... ts with advanced solid tumors.
@ast
Phase I trial of weekly trabec ...... ts with advanced solid tumors.
@en
prefLabel
Phase I trial of weekly trabec ...... ts with advanced solid tumors.
@ast
Phase I trial of weekly trabec ...... ts with advanced solid tumors.
@en
P2093
P2860
P1476
Phase I trial of weekly trabec ...... nts with advanced solid tumors
@en
P2093
Antonio Jimeno
Dan Laheru
David Ettinger
Dina Lansey
Julie Brahmer
Peter Zannikos
Ross C Donehower
Wells A Messersmith
Yasmin Khan
Yusri Elsayed
P2860
P2888
P304
P356
10.1007/S00280-008-0733-7
P577
2008-04-01T00:00:00Z